The study is devoted to the analysis of the problem of legal regulation of the pharmaceutical
industry, the development of pharmaceutical science and practice in the context of the COVID-19
pandemic. Based on the scientific methods of legal analysis, comparative studies, and modeling,
conclusions are substantiated about the preservation of the priorities of scientists in pharmaceutical
practice, which do not change in the light of COVID-19, but must be adapted to the pandemic; on the
need to take into account the value of pharmaceutical services in health emergencies, the logistics of
delivery using the Internet and other technologies, the viability and optimization of pharmacological
therapies given the ubiquitous presence of a deadly virus, the deployment of support staff; about the
feasibility of pharmaceutical practitioners being at the forefront of treatment evaluation and
communication strategies that improve adherence to those treatments and lead to meaningful outcomes;
on the need to modernize the legal regulation of the pharmaceutical industry.